Secukinumab and concomitant antibiotic use in patients with moderate-to-severe hidradenitis suppurativa: Week 16 efficacy and safety results from the Phase 3 SUNSHINE and SUNRISE trials

被引：0

作者：

Kokolakis, Georgios ^{[1
,2
,3
]}

Martorell, Antonio ^{[4
]}

Kerdel, Francisco ^{[5
]}

Bettoli, Vincenzo ^{[6
]}

Giamarellos-Bourboulis, Evangelos J. ^{[7
]}

Sinclair, Rodney ^{[8
]}

Kasparek, Torben ^{[9
]}

Li, Xianjun ^{[10
]}

Martinez, Angela Llobet ^{[9
]}

Uhlmann, Lorenz ^{[9
]}

Muscianisi, Elisa ^{[11
]}

机构：

[1] Charite Univ Med Berlin, Psoriasis Res & Treatment Ctr, Dept Dermatol Venereol & Allergol, Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] Hosp Manises, Dept Dermatol, Valencia, Spain

[5] Florida Acad Ctr Res & Educ, Coral Gables, FL USA

[6] Azienda Osped Univ Ferrara, Dept Oncol & Specialist Med, OU Dermatol, Ferrara, Italy

[7] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med 4, Athens, Greece

[8] Sinclair Dermatol, Melbourne, Vic, Australia

[9] Novartis Pharma AG, Basel, Switzerland

[10] Novartis Pharmaceut, Shanghai, Peoples R China

[11] Novartis Pharmaceut, E Hanover, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

42981

引用

页码：AB85 / AB85

页数：1

共 50 条

[31] Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomized trial
Magnolo, Nina
Kingo, Kulli
Laquer, Vivian
Browning, John
Reich, Adam
Szepietowski, Jacek C.
Keefe, Deborah
Mazur, Rafal
Ghelani, Prayashi
Forrer, Pascal
Patekar, Manmath
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB119 - AB119
[32] Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials
Kimball, Alexandra B.
Sundaram, Murali
Shields, Alan L.
Hudgens, Stacie
Okun, Martin
Foley, Catherine
Ganguli, Arijit
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (06) : 1141 - 1143
[33] Effectiveness, safety and potential predictors of response at week 16 in patients with severe hidradenitis suppurativa treated with secukinumab: A multicenter observational retrospective study
Serrano, Pablo Fernandez-Crehuet
Haselgruber-deFrancisco, Sofia
Padial-Gomez, Alicia
Vasquez-Chinchay, Fiorella
Fernandez-Ballesteros, Maria D.
Lopez-Riquelme, Irene
Jimenez-Gallo, David
Segura-Palacios, Juan M.
Contreras-Steyls, Marisol
Osorio-Gomez, Guiovana F.
Hernandez-Rodriguez, Juan Carlos
Cuenca-Barrales, Carlos
Molina-Leyva, Alejandro
EXPERIMENTAL DERMATOLOGY, 2023, 32 : 108 - 108
[34] International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab
Zouboulis, Christos C.
Prens, Errol P.
Sayed, Christopher J.
Molina-Leyva, Alejandro
Bettoli, Vincenzo
Romanelli, Marco
Szepietowski, Jacek C.
Martinez, Angela Llobet
Kasparek, Torben
Lobach, Iryna
Wozniak, Magdalena B.
Ortmann, Christine-Elke
Thomas, Nicolas
Bachhuber, Teresa
Ravichandran, Shoba
Tzellos, Thrasyvoulos
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (06) : e496 - e499
[35] Efficacy and safety of risankizumab, an Il-23 inihibitor in patients with moderate-to-severe chronic Plaque Psoriasis: 16-week Phase 3 IMMhance Trial results
Blauvelt, A.
Papp, K.
Gooderham, M.
Langley, R. G.
Leonardi, C.
Lacour, J. P.
Philipp, S.
Tyring, S.
Bukhalo, M.
Wu, J. J.
Bagel, J.
Frankel, E. H.
Pariser, D.
Flack, M.
Scherer, J.
Geng, Z.
Gu, Y.
Camez, A.
Thompson, E. H. Z.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 18 - 18
[36] Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
Fiorillo, Loretta
Becker, Emily
de Lucas, Raul
Belloni-Fortina, Anna
Armesto, Susana
Elewski, Boni
Maes, Peter
Oberoi, Rajneet K.
Paris, Maria
Zhang, Wendy
Zhang, Zuoshun
Arkin, Lisa
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (06) : 1232 - 1239
[37] Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
Danese, S.
Sands, B. E.
O'Brien, C. D.
Zhang, H.
Johanns, J.
Sloan, S.
Izanec, J.
Szapary, P.
Marano, C.
Leong, R. W.
Rowbotham, D.
Targan, S. R.
Van Assche, G.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S61 - S62
[38] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response and Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
Elewski, B.
Lebwohl, M.
Papp, K.
Nakagawa, H.
Sigurgeirsson, B.
Tsai, T. -F.
Tyring, S.
Hampele, I.
Karpov, A.
Helou, S.
Papavassilis, C.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 43 - 43
[39] Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Clowse, Megan E. B.
Wallace, Daniel J.
Furie, Richard
Petri, Michelle
Pike, Marilyn
Leszczynski, Piotr
Neuwelt, C. Michael
Hobbs, Kathryn
Keiserman, Mauro
Duca, Liliana
Kalunian, Kenneth
Bongardt, Sabine
Stach, Christian
Beaudot, Carolyn
Kilgallen, Brian
Galateanu, Catrinel
Gordon, Caroline
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[40] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response And Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
Elewski, B.
Lebwohl, M.
Papp, K.
Nakagawa, H.
Sigurgeirsson, B.
Tsai, T.
Tyring, S.
Hampele, I.
Karpov, A.
Helou, S.
Papavassilis, C.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 15 - 15

← 1 2 3 4 5 →